Vitiligo: advances in pathophysiology research and treatment development

dc.contributor.authorLe Poole, I. Caroline
dc.contributor.authorMukhatayev, Zhussipbek
dc.contributor.institutionNazarbayev University
dc.date.accessioned2025
dc.date.issued2024
dc.description.abstractThe autoimmune condition vitiligo, characterized by skin depigmentation, presents challenges for effective treatment design, with Janus kinase (JAK) inhibitors and other repurposed drugs offering a promising strategy for symptom management. This review explores advantages and shortcomings of current therapies, while presenting the urgent need for further innovative approaches. We emphasize the growing understanding of autoimmune involvement in vitiligo, highlighting several novel treatment avenues including relieving melanocyte stress, preventing dendritic cell activation, halting T cell migration, and suppressing inflammation and autoimmunity. Integrating psychodrama therapy to remediate stress alongside medical interventions marks a holistic approach to enhance patient well-being. The molecular underpinnings of vitiligo care are covered, emphasizing exciting advances revolutionizing vitiligo treatment and improving the quality of life for affected individuals.
dc.identifier.doi10.1016/j.molmed.2024.04.009
dc.identifier.urihttps://doi.org/10.1016/j.molmed.2024.04.009
dc.identifier.urihttps://nur.nu.edu.kz/handle/123456789/13899
dc.languageen
dc.publisherTrends in Molecular Medicine
dc.rightsMetadata only
dc.sourceTrends in Molecular Medicine, 30(9), 844-862
dc.subjectNursing
dc.subjectPsychiatry
dc.subjectDermatology
dc.subjectImmune system
dc.subjectImmunology
dc.subjectQuality of life (healthcare)
dc.subjectDepigmentation
dc.subjectPsychological intervention
dc.subjectPsoriasis
dc.subjectAutoimmunity
dc.subjectMedicine
dc.subjectVitiligo
dc.titleVitiligo: advances in pathophysiology research and treatment development
dc.typeArticle

Files

Collections